OPA 15406

Drug Profile

OPA 15406

Alternative Names: MM 36; MM36-Medimetriks Pharmaceuticals; OPA-15406

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Otsuka Pharmaceutical Development & Commercialization
  • Developer Medimetriks Pharmaceuticals; Otsuka Pharmaceutical Development & Commercialization
  • Class Skin disorder therapies
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis

Most Recent Events

  • 06 Sep 2017 Medimetriks Pharmaceuticals announces intention to submit NDA to US FDA for Atopic dermatitis in the second half of 2019
  • 06 Sep 2017 Efficacy and adverse events data from the phase II MUSE trial in Atopic dermatitis released by Medimetriks Pharmaceuticals
  • 06 Sep 2017 Medimetriks Pharmaceuticals completes the phase II MUSE trial in Atopic dermatitis (In adolescents, In children) in Honduras, Panama and USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top